"Anyhow great to see the SP here steadily get back to higher levels and not the $1.50 previously mentioned."
The $1.50 price was wishful thinking (for the shorts anyway!). That price suggested ACR was not going to make any further milestone payments while Axiron's share of the US market didn't get much higher than 15% before fading post 2017... (with the patient expiry and generics)
If you believe they can make the milestone - that's US$195m if they (lilly) can achieve the net sales targets. even if you risk weight those payments by 15% they are worth 80c per share on top of a Axiron royalty stream worth upward of $3-$4.
As for new products / pipeline - I've given up trying to value that :-) not holding my breath here!!
Regards,
Mita
ACR Price at posting:
$2.72 Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)